Myeloma Clinical Trials
6 recruiting trials for Myeloma. Eligibility criteria explained in plain English.
TrialFinderData lists 6 Myeloma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 is the largest group at 67% (2 studies); the largest phase groups are Phase 1: 2, Phase 2 / Phase 3: 1.
Research is led by University Hospital, Angers (1), The Affiliated People's Hospital of Ningbo University (1), A.O. Ospedale Papa Giovanni XXIII (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Drug skin tests (investigating hypersensitivity to a biotherapy) (other, 1 trial), followed by Autologous CAR-T cells, Fludarabine.
Track Myeloma trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory...
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.
Bergamo Lymphoid Cancer Registry
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as...
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients...
European Rare Blood Disorders Platform (ENROL)
ENROL, the European Rare Blood Disorders Platform has been conceived in the core of ERN-EuroBloodNet as an umbrella for both new and already existing registries on Rare...
Explore Other Conditions
Frequently Asked Questions
There are currently 6 clinical trials for Myeloma, with 6 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Myeloma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Myeloma, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.